Solution
Identifying patients who are truly at risk for hypersensitivity reactions to PEG-containing products remains a persistent challenge in allergy diagnostics. Allergen-specific IgE is central to classical type I hypersensitivity and IgE-mediated anaphylaxis. However, before PEG-specific IgE could be reliably detected, PEG-associated reactions were often attributed primarily to non-IgE-mediated mechanisms, including complement activation-related pseudoallergy (CARPA), with anti-PEG IgG/IgM considered a possible contributor.
Yet the high prevalence of anti-PEG IgG/IgM in the general population contrasts sharply with the relatively low incidence of PEG-induced anaphylaxis. This discrepancy suggests that anti-PEG IgG/IgM alone is unlikely to fully explain clinically significant PEG hypersensitivity. Therefore, our focus is on the detection and clinical interpretation of anti-PEG IgE as a more relevant marker for identifying patients at risk of immediate hypersensitivity reactions to PEG-containing products.
Conventional PEG skin testing for suspected type I hypersensitivity has been reported to show high specificity, approximately 99%, but limited sensitivity, approximately 59%. Thus, a positive PEG skin test may strongly support PEG sensitization, whereas a negative result does not reliably exclude PEG-mediated immediate hypersensitivity. In addition, skin testing carries an inherent risk of provoking allergic reactions, including systemic reactions and anaphylaxis. Compared with skin testing, an in vitro blood-based assay for anti-PEG IgE provides a safer and potentially more sensitive approach for evaluating PEG sensitization. However, because PEG-specific IgE is typically present at very low abundance and is difficult to distinguish from assay background, only a limited number of laboratories are currently able to detect anti-PEG IgE reliably.
The FocalTuning™ platform is designed to address this diagnostic gap. By integrating proprietary signal-deconvolution methods with precision background-correction technologies, FocalTuning™ enables highly sensitive, specific, and accurate detection of anti-PEG IgE. The platform accounts for both patient-specific background and matrix-specific background, helping to reduce false-negative and false-positive results compared with conventional allergen-specific IgE detection platforms.
This improved analytical performance helps distinguish true immunologic reactivity from nonspecific assay interference, thereby increasing diagnostic confidence. By enabling more reliable detection of anti-PEG IgE, FocalTuning™ provides a safer, more informative, and biologically relevant solution for assessing the risk of PEG-associated anaphylaxis.
Human PEG IgE Detection Kit
